Prices for innovative pharmaceutical products that provide health gain: A comparison between Australia and the United States

Value in Health

Volumn 10, Issue 6, 2007, Pages 514-520

  Roughead, Elizabeth E ^a   Lopert, Ruth ^b   Sansom, Lloyd Norman ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Australia; Innovation; Pharmaceutical prices; Trade agreements; United States

Indexed keywords

ARTICLE; AUSTRALIA; COMPARATIVE STUDY; DRUG COST; DRUG MANUFACTURE; PRIORITY JOURNAL; UNITED STATES;

AUSTRALIA; DRUG COSTS; HUMANS; INTERNATIONALITY; NATIONAL HEALTH PROGRAMS; RATE SETTING AND REVIEW; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 35549013688     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00206.x     Document Type: Article

References (32)

1. United States of America. Trade Promotion Authority Act. 2002.
2. Testimony of Under Secretary of Commerce for International Trade Grant D. Aldonas Before a Joint Session of the Senate Finance Committee, Subcommittees on Health and Trade. Washington, 2004. Available from: http://canada.usembassy. gov/content/can_usa/pharmaceuticals_042704.pdf [Accessed May 5, 2006].
3. Food and Drug Administration. Speech Before First International Colloquium on Generic Medicine. 2003. Available from: http://www.fda.gov/oc/ speeches/2003/genericdrug0925.html [Accessed May 5, 2006].
4. US Department of Commerce. Pharmaceutical Price Controls in OECD Countries. Implications for U.S. Consumers, Pricing, Research and Development, and Innovation. Washington, DC : US Department of Commerce, International Trade Administration, 2004.
5. Light DW, Lexchin J. Foreign free riders and the high price of US medicines. BMJ 2005 331 : 958 60.
6. Australian Government Department of Foreign Affairs and Trade. Australia-US Free Trade Agreement. Chapter 2: National Treatment and Market Access for Goods. 2004. Available from: http://www.dfat.gov.au/trade/ negotiations/us_fta/final-text/chapter_2.html [Accessed June 8, 2006].
7. Sansom LN. The subsidy of pharmaceuticals in Australia: processes and challenges. Aust Health Rev 2004 28 : 194 205.
8. Henry D, Lopert R. Pharmacoeconomics and policy decisions: the Australian health care system. Clin Ther 1999 21 : 909 15.
9. Productivity Commission. International Pharmaceutical Price Differences. Canberra : Ausinfo, 2001.
10. Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff (Millwood) 2003 Suppl. Web Exclusives W3 521-36.
11. Productivity Commission. The Pharmaceutical Industry. Canberra : Australian Government Publishing Service, 1996. Report No. 51.
12. Motola D, De Ponti F, Rossi P, et al. Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. Br J Clin Pharmacol 2005 59 : 475 8.
13. Patented Medicines Prices Review Board. Annual Reports 2000-2004. 2005. Available from: http://www.pmprb-cepmb.gc.ca/english/view.asp?x=91 [Accessed May 3, 2006].
14. Food and Drug Administration. CDER Fast Track Products Approved Since 1998 through March 31, 2006. 2006. Available from: http://www.fda.gov/cder/rdmt/ internetftap.htm [Accessed May 3, 2006].
15. US Department of Veterans Affairs. Consolidated FSS, Big4 and Restricted FSS (VA Only) Prices. 2006. Available from: http://www.pbm.va.gov/PBM/prices.htm [Accessed May 3, 2006].
16. Price Waterhouse Coopers LLP. HCFA Study of the Pharmaceutical Benefit Management Industry. Atlanta : Price Waterhouse Coopers LLP, 2001.
17. United States of America. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. 2004.
18. Centers for Medicare and Medicaid Services. April 2006 ASP pricing file. 2006. Available from: http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/ 02_aspfiles.asp#TopOfPage [Accessed November 3, 2006].
19. Micromedex. 2006 Red Book. Montvale, NJ : Thomson PDR, 2006.
20. Australian Government Department of Health and Ageing. Schedule of Pharmaceutical Benefits 1 April 2006. Canberra : National Capital Printing, 2006.
21. XE Corporation. The universal currency converter. 2006. Available from: http://www.xe.com/ucc/ [Accessed May 3, 2006].
22. OECD. Purchasing Power Parities - Parites de pouvoir d'Achat, Comparative Price Levels - Niveaux de prix compares. Paris : OECD, 2006.
23. US Department of Health and Human Services. Indian Health Service Fact Sheet. 2006. Available from: http://www.ihs.gov/PublicInfo/PublicAffairs/ Welcome_Info/ThisFacts.asp [Accessed June 16, 2006].
24. US Department of Veterans Affairs. Fact Sheet: Facts About the Department of Veterans Affairs. 2006. Available from: http://www1.va.gov/opa/fact/vafacts. asp [Accessed June 16, 2006].
25. Tricare Management Activity. Beneficiary Statistics by State. Tricare, 2005. Available from: http://www.tricare.osd.mil/media/bene_stat.cfm [Accessed June 16, 2006].
26. Australian Bureau of Statistics (ABS). Population by Age and Sex, Australian States and Territories. Cat, No. 3201.0. Canberra : ABS, 2005.
27. Hagens Berman Sobol Shapiro LLP. First Databank Litigation Exhibit A to Settlement Agreement. 2006. Available from: http://www.hbsslaw.com/ first_data_bank_settlement.htm;jsessionid=azqBqr0UJNb8 [Accessed November 16, 2006].
28. Pharmaceutical Giants Lose Key Court Ruling on "Average Wholesale Price" Litigation. PRnewswire, November 2, 2006.
29. Australian Government. Public Summary Documents. 2006. Available from: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ public-summary-documents [Accessed June 16, 2006].
30. Decision Resources Inc. 2005 Chartbook of International Pharmaceutical Prices. Research and Markets. 2005. Available from: http://www. researchandmarkets.com/reports/c32018/ [Accessed June 8, 2006].
31. OECD. Survey of Pharmacoeconomic Assessment Activity in Eleven Countries. 2003. Available from: http://www.ispor.org/news/articles/Feb04/survey.asp [Accessed May 5, 2006].
32. Congressional Budget Office. Prices for Brand-Name Drugs Under Selected Federal Programs. Washington, DC : Congressional Budget Office, 2005.